<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176265</url>
  </required_header>
  <id_info>
    <org_study_id>QUEST I</org_study_id>
    <nct_id>NCT02176265</nct_id>
  </id_info>
  <brief_title>Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation</brief_title>
  <official_title>Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qvanteq AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardialysis BV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Qvanteq AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective of this First in Man study is to assess feasibility and safety of Qvanteq's
      bioactive coronary stent for treatment of stable coronary artery disease patients with de
      novo coronary artery stenosis in native vessels.

      The proprietary surface of Qvanteq's bioactive coronary stent improves the in-growth behavior
      of the stent in the treated vessel. In-vivo animal studies revealed fast in-growth (similar
      to BMS), which however is not resulting in excessive tissue overgrowth as observed in BMS but
      rather has an efficacy profile similar to drug-eluting stent (DES), meaning suppression of
      tissue overgrowth. This should reduce the risk of restenosis and thrombus formation despite
      the presence of a short term dual anti platelet therapy (DAPT). Furthermore, prolonged DAPT
      time as applied with current DES increases the bleeding risk of patients.

      The study is a prospective, multicenter, open-label, single arm study; conducted in up to 6
      cardiology centers in CH and NL. In total, approx. 35 patients will be enrolled. All patients
      will be treated with the Qvanteq's bioactive coronary stent. Clinical follow-up will occur at
      1, 6 &amp; 12 months post-stent implantation. All patients will undergo angiography assessment
      (QCA) and Optical Coherence Tomography investigation (OCT) at baseline and at 6 months
      follow-up. Baseline OCT should be performed after the successfully completed angiographic
      procedure (documentary OCT). 1 and 12 months clinical follow-ups are conducted via telephone.

      Primary Angiographic endpoint is in-stent Late Lumen Loss at 6 months; assessed by off-line
      QCA. Primary OCT endpoint is mean neointimal thickness at 6 months; assessed by off-line OCT
      analysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent Late Lumen Loss (LLL) assessed by off-line QCA</measure>
    <time_frame>At 6 months after stent implantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean neointimal thickness assessed by off-line OCT analysis</measure>
    <time_frame>At 6 months after stent implantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute lumen gain assessed by off-line QCA</measure>
    <time_frame>At 6 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment Late Lumen Loss assessed by off-line QCA</measure>
    <time_frame>At 6 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Lumen Diameter (MLD) assessed by off-line QCA</measure>
    <time_frame>At 6 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diameter stenosis assessed by off-line QCA</measure>
    <time_frame>At 6 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis (diameter stenosis &gt; = 50%) assessed by off-line QCA</measure>
    <time_frame>At 6 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolapse area/volume assessed by off-line OCT analysis</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/minimal lumen diameter/area/volume assessed by off-line OCT analysis</measure>
    <time_frame>At baseline and at 6 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/minimal stent diameter/area/volume assessed by off-line OCT analysis</measure>
    <time_frame>At baseline and at 6 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent symmetry assessed by off-line OCT analysis</measure>
    <time_frame>At baseline and at 6 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent expansion assessed by off-line OCT analysis</measure>
    <time_frame>At baseline and at 6 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incomplete strut apposition assessed by off-line OCT analysis</measure>
    <time_frame>At baseline and at 6 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent neointimal hyperplasia volume obstruction (%) assessed by off-line OCT analysis</measure>
    <time_frame>At 6 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neointimal hyperplasia area/volume assessed by off-line OCT analysis</measure>
    <time_frame>At 6 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/maximal thickness of the struts coverage assessed by off-line OCT analysis</measure>
    <time_frame>At 6 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage number of covered struts assessed by off-line OCT analysis</measure>
    <time_frame>At 6 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of incomplete apposed struts assessed by off-line OCT analysis</measure>
    <time_frame>At 6 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healing score assessed by off-line OCT analysis</measure>
    <time_frame>At 6 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute success (device and procedural)</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device-oriented composite endpoints (cardiac death, MI not clearly attributable to a non-intervention vessel, clinically indicated target lesion revascularization)</measure>
    <time_frame>At 1, 6 and 12 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (Q-wave, Non q-wave)</measure>
    <time_frame>At 1, 6 and 12 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically indicated revascularization of the target vessel</measure>
    <time_frame>At 1, 6 and 12 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any revascularization</measure>
    <time_frame>At 1, 6 and 12 months after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis according to ARC definitions</measure>
    <time_frame>Up to 12 months after stent implantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Qvanteq bioactive coronary stent system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, single arm, non-randomized study</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Qvanteq bioactive coronary stent</intervention_name>
    <description>PCI</description>
    <arm_group_label>Qvanteq bioactive coronary stent system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be at least 18 years of age

          -  Evidence of myocardial ischemia without elevated cardiac biomarkers (e.g. stable or
             unstable angina with stable haemodynamic condition, silent ischemia demonstrated by
             positive territorial functional study)

          -  The patient has a planned intervention of one single de novo lesion in one or two
             separate major epicardial territories (LAD, LCX, or RCA).

          -  The lesion must have a visually estimated diameter stenosis of ≥ 50% and &lt; 100%

          -  Lesion length must be ≤16 mm

          -  The vessel size must be between 2.5 and 3.5 mm

          -  Written informed consent

          -  The patient agrees to the follow-up visits including angiographic follow-up and OCT
             control at 6 months

        Key Exclusion Criteria:

          -  Evidence of ongoing acute myocardial infarction (AMI) in ECG and/or elevated cardiac
             biomarkers (according to local standard hospital practice) have not returned within
             normal limits at the time of procedure.

          -  Patient suffered from stroke/TIA or myocardial infarction during the last 6 months

          -  LVEF &lt;30%

          -  Platelet count &lt;100,000 cells/mm3 or &gt;400,000 cells/mm3, a WBC of &lt;3,000 cells/mm3, or
             documented or suspected liver disease (including laboratory evidence of hepatitis)

          -  Known renal insufficiency (Creatinine clearance less than 30 mL/Min), or subject on
             dialysis, or acute kidney failure

          -  Patient undergoing planned surgery within 6 months with the necessity to stop ASA

          -  Patient requiring prolonged DAPT for other diagnoses (&gt;1 month)

          -  History of bleeding diathesis or coagulopathy

          -  Patient requiring oral anticoagulation (Coumadin, NOAC)

          -  The patient is a recipient of a heart transplant

          -  Known hypersensitivity or contraindication to aspirin, heparin, clopidogrel or
             cobalt-chromium

          -  Other medical illness (e.g. cancer, stroke with neurological deficiency) or known
             history of substance abuse (alcohol, cocaine, heroin etc.) as per physician judgment
             that may cause non-compliance with the protocol or confound the data interpretation or
             is associated with a limited life expectancy

          -  Female of child bearing potential (age &lt;50 years and last menstruation within the last
             12 months), who did not underwent tubal ligation, ovariectomy or hysterectomy.

          -  Previous CABG

        Angiographic Exclusion Criteria:

          -  Severe tortuous, calcified or angulated coronary anatomy of the study vessel that in
             the opinion of the investigator would result in suboptimal imaging or excessive risk
             of complication from placement of an OCT catheter

          -  Target lesion in left main stem.

          -  Target lesion involves a side branch &gt; 2.0mm in diameter

          -  Aorto-ostial target lesion (within 3 mm of the aorta junction).

          -  Total occlusion or TIMI flow &lt;3, prior to wire crossing

          -  The target vessel contains visible thrombus

          -  Restenotic lesion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorenz Räber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep. of Cardiology, University Hospital Bern, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick W Serruys, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Erasmus Medical Center, Thoraxcenter, Rotterdam, the Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thoraxcentrum Twente, Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7513</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxcenter Erasmus MC Universitair Medisch Centrum Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Kardiologie Schweizer Herz- und Gefässzentrum Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiologie interventionnelle HUG - Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HerzKlinik Hirslanden</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli Zürich Klinik für Kardiologie</name>
      <address>
        <city>Zürich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007 Feb 24;369(9562):667-78.</citation>
    <PMID>17321312</PMID>
  </reference>
  <reference>
    <citation>Räber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, Wenaweser P, Daemen J, Meier B, Jüni P, Serruys PW, Windecker S. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation. 2012 Mar 6;125(9):1110-21. doi: 10.1161/CIRCULATIONAHA.111.058560. Epub 2012 Feb 1.</citation>
    <PMID>22302840</PMID>
  </reference>
  <reference>
    <citation>Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010 Jan 16;375(9710):201-9. doi: 10.1016/S0140-6736(09)62127-9. Epub 2010 Jan 7.</citation>
    <PMID>20060578</PMID>
  </reference>
  <reference>
    <citation>Ndrepepa G, Schuster T, Hadamitzky M, Byrne RA, Mehilli J, Neumann FJ, Richardt G, Schulz S, Laugwitz KL, Massberg S, Schömig A, Kastrati A. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation. 2012 Mar 20;125(11):1424-31. doi: 10.1161/CIRCULATIONAHA.111.060871. Epub 2012 Feb 17.</citation>
    <PMID>22344040</PMID>
  </reference>
  <reference>
    <citation>Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007 May 8;115(18):2435-41. Epub 2007 Apr 16.</citation>
    <PMID>17438147</PMID>
  </reference>
  <reference>
    <citation>Guagliumi G, Sirbu V, Musumeci G, Gerber R, Biondi-Zoccai G, Ikejima H, Ladich E, Lortkipanidze N, Matiashvili A, Valsecchi O, Virmani R, Stone GW. Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging. JACC Cardiovasc Interv. 2012 Jan;5(1):12-20. doi: 10.1016/j.jcin.2011.09.018.</citation>
    <PMID>22230145</PMID>
  </reference>
  <reference>
    <citation>Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C; BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006 Dec 19;48(12):2584-91. Epub 2006 Nov 2.</citation>
    <PMID>17174201</PMID>
  </reference>
  <reference>
    <citation>Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007 Jan 10;297(2):159-68. Epub 2006 Dec 5.</citation>
    <PMID>17148711</PMID>
  </reference>
  <reference>
    <citation>Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ, Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang JS, Park HS, Lee K. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med. 2010 Apr 15;362(15):1374-82. doi: 10.1056/NEJMoa1001266. Epub 2010 Mar 15.</citation>
    <PMID>20231231</PMID>
  </reference>
  <reference>
    <citation>Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012 Jan 24;125(3):505-13. doi: 10.1161/CIRCULATIONAHA.111.059022. Epub 2011 Dec 16.</citation>
    <PMID>22179532</PMID>
  </reference>
  <reference>
    <citation>Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, Colombo F, Tebaldi M, Fucà G, Kubbajeh M, Cangiano E, Minarelli M, Scalone A, Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012 Apr 24;125(16):2015-26. doi: 10.1161/CIRCULATIONAHA.111.071589. Epub 2012 Mar 21.</citation>
    <PMID>22438530</PMID>
  </reference>
  <reference>
    <citation>Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D. Guidelines on myocardial revascularization. Eur Heart J. 2010 Oct;31(20):2501-55. doi: 10.1093/eurheartj/ehq277. Epub 2010 Aug 29.</citation>
    <PMID>20802248</PMID>
  </reference>
  <reference>
    <citation>Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449.</citation>
    <PMID>21670242</PMID>
  </reference>
  <reference>
    <citation>Soehnlein O, Wantha S, Simsekyilmaz S, Döring Y, Megens RT, Mause SF, Drechsler M, Smeets R, Weinandy S, Schreiber F, Gries T, Jockenhoevel S, Möller M, Vijayan S, van Zandvoort MA, Agerberth B, Pham CT, Gallo RL, Hackeng TM, Liehn EA, Zernecke A, Klee D, Weber C. Neutrophil-derived cathelicidin protects from neointimal hyperplasia. Sci Transl Med. 2011 Oct 5;3(103):103ra98. doi: 10.1126/scitranslmed.3002531.</citation>
    <PMID>21974936</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>September 2, 2016</last_update_submitted>
  <last_update_submitted_qc>September 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAD</keyword>
  <keyword>PCI</keyword>
  <keyword>bioactive coronary stent</keyword>
  <keyword>OCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

